Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. FDX
6. IBM
7. MU
8. ACN
9. USO
10. NVDA

Go back to Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)
(NYSE: TAK) Delayed: 15.84 +0.37 (2.39%)
Previous Close $15.47    52 Week High $0.55 
Open $15.65    52 Week Low $0.55 
Day High $15.85    P/E N/A 
Day Low $15.50    EPS $-0.20 
Volume 3,126,624